2. Search Result
Search Result
Results for "

prion diseases

" in MedChemExpress (MCE) Product Catalog:

12

Inhibitors & Agonists

1

Peptides

1

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-15728
    Radotinib

    IY-5511

    		 Bcr-Abl Apoptosis STAT JAK Prion Protein Infection Neurological Disease Cancer
    Radotinib (IY-5511) is an orally active and BBB-permeable selective tyrosine kinase Bcr-Abl1 inhibitor with an IC50 of 34 nM. Radotinib has anti-prion and anti-tumor activities. Radotinib can inhibit the proliferation, induce cell cycle arrest and apoptosis of tumor cells . Radotinib can be used in the research of cancer such as chronic myeloid leukemia and multiple myeloma, as well as neurodegenerative diseases such as prion diseases .
    Radotinib
  • HY-101855
    Emrusolmin

    Anle138b

    		 Amyloid-β Neurological Disease
    Emrusolmin (Anle138b), an oligomeric aggregation inhibitor, blocks the formation of pathological aggregates of prion protein (PrPSc) and of α-synuclein (α-syn). Emrusolmin strongly inhibits oligomer accumulation, neuronal degeneration, and disease progression in vivo. Emrusolmin has low toxicity and an excellent oral bioavailability and blood-brain-barrier penetration. Emrusolmin blocks Aβ channels and rescues disease phenotypes in a mouse model for amyloid pathology .
    Emrusolmin
  • HY-122066
    NSC47924

    		Others Infection
    NSC47924 is a laminin receptor (LR) inhibitor. NSC47924 affects 37/67 kDa LR cell surface localization and interaction with the cellular prion protein. NSC47924 can be used for testing prion diseases .
    NSC47924
  • HY-P10534
    ccβ

    		Prion Protein Infection Neurological Disease
    CCβ is a simple 17-amino acid peptide designed in research. CCβ is able to mimic the conformational transition of proteins from α-helix to β-sheet, which is a key step in the aggregation of proteins associated with many diseases, such as Alzheimer's disease and prion disease. CCβ can be used to study diseases related to protein aggregation .
    ccβ
  • HY-150286
    SM875

    		Prion Protein Neurological Disease
    SM875 is a cellular prion protein (PrP) degrader (IC50: 7.87 μM). SM875 targets PrP folding intermediates and promotes its degradation through the autophagy-lysosomal pathway. SM875 only acts on nascent, immature PrP molecules and has no effect on mature PrP before synthesis. SM875 can inhibit prion replication and has potential in the study of neurodegenerative diseases (i.e., prion diseases) .
    SM875
  • HY-115360
    IND45193

    		Prion Protein Others
    IND45193 is a compound used to inhibit prion disease, with activity in reducing PrP(Sc) levels. In cells infected with prions, IND45193 can reduce PrP(Sc) levels, and its activity was determined through screening of multiple cell types and concentration-effect relationship studies.
    IND45193
  • HY-15728S
    Radotinib-d6

    IY-5511-d6

    		 Isotope-Labeled Compounds Bcr-Abl Apoptosis STAT JAK Prion Protein Infection Neurological Disease Cancer
    Radotinib-d6 is deuterium labeled Radotinib (HY-15728). Radotinib (IY-5511) is an orally active and BBB-permeable selective tyrosine kinase Bcr-Abl1 inhibitor with an IC50 of 34 nM. Radotinib has anti-prion and anti-tumor activities. Radotinib can inhibit the proliferation, induce cell cycle arrest and apoptosis of tumor cells . Radotinib can be used in the research of cancer such as chronic myeloid leukemia and multiple myeloma, as well as neurodegenerative diseases such as prion diseases .
    Radotinib-d6
  • HY-153427
    Tau protein aggregation-IN-1

    		Tau Protein Neurological Disease
    Tau protein aggregation-IN-1 (Compound 0c) is a Tau protein aggregation inhibitor. Tau protein aggregation-IN-1 can be used in the study of protein folding disorders such as Alzheimer's disease, dementia, Parkinson's disease, Huntington's disease and prion-based spongiform encephalopathies .
    Tau protein aggregation-IN-1
  • HY-124375
    IND81

    		Prion Protein Infection
    IND81 is an orally active antiprion with IC50 value of 1.95 μM. IND81 reduces abnormal, misfolded, disease-causing forms of benign prion proteins that are normally present on or within cells .
    IND81
  • HY-147702
    BB 0305179

    		Prion Protein Infection Neurological Disease
    BB 0305179 (compound 59) is a potent anti-prion agent, with an IC50 of 4.7 μM. BB 0305179 inhibits the toxicity of a specific PrP mutant carrying a deletion in the hydrophobic domain . BB 0305179 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    BB 0305179
  • HY-160831
    PQQ-trimethylester

    PQQ-TME

    		 α-synuclein Neurological Disease
    PQQ-trimethylester (PQQ-TME) is a synthetic compound that is a trimethylester derivative of pyrroloquinoline quinone (PQQ). PQQ-trimethylester has twice the blood-brain barrier permeability of PQQ (HY-100196) in vitro. In addition, PQQ-trimethylester shows strong inhibitory activity against α-synuclein, amyloid β1-42 (Aβ1-42) and prion protein fibrillation. PQQ-trimethylester can be used in the study of neurodegenerative diseases .
    PQQ-trimethylester
  • HY-147371
    Quinoprazine

    		Parasite Infection Neurological Disease
    Quinoprazine is a potent inhibitor of Vaccinia virus DNA synthesis with an IC50 value of 10 μM. Quinoprazine has antimalarial activity against Plasmodium berghei and also displays antiprion potency, significantly decreases PrP S c levels - .
    Quinoprazine

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: